Moderna (MRNA) Other Non-Current Assets (2017 - 2026)

Moderna (MRNA) has 10 years of Other Non-Current Assets data on file, last reported at $675.0 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $675.0 million, up 21.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $675.0 million (up 21.4% YoY), and the FY2025 annual result was $605.0 million, up 1.85% from the prior year.
• Other Non-Current Assets advanced to $675.0 million in Q1 2026 per MRNA's latest filing, from $605.0 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $1.3 billion in Q2 2023 and troughed at $12.0 million in Q1 2022.
• A 5-year average of $607.2 million and a median of $605.0 million in 2025 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Assets soared 9600.0% in 2023, then plunged 50.31% in 2024.
• A 5-year view of Other Non-Current Assets shows it stood at $988.0 million in 2022, then fell by 22.47% to $766.0 million in 2023, then retreated by 22.45% to $594.0 million in 2024, then gained by 1.85% to $605.0 million in 2025, then grew by 11.57% to $675.0 million in 2026.
• Business Quant data shows MRNA's Other Non-Current Assets at $675.0 million in Q1 2026, $605.0 million in Q4 2025, and $530.0 million in Q3 2025.